The microbiology of Bacterial Vaginosis represents a complex change in the vaginal flora, which is characterized by a reduction in the concentration of the normally dominant hydrogen-peroxide producing lactobacilli, as well as an increase in concentration of other organisms, particularly anaerobic gram negative rods. The administration of clindamycin administered either orally or intravaginally has proven effectual and safe. In fact, almost 80 percent of patients treated with clindamycin for Bacterial Vaginosis experience a high rate of clinical cure at a four week follow up. Topical vaginal therapy with a 2 percent clindamycin cream (5 g of cream containing 100 mg of clindamycin phosphate) is the recommended dose for Bacterial Vaginosis, to be administered as a seven day regimen. It is important for patients to know that Clindamycin cream should not be used concurrently with latex condoms, as it may weaken the condom.
Bacterial Vaginosis is diagnosed by the presence of homogeneous vaginal discharge, a presence of clue cells greater than 20 percent, absence of the normal vaginal lactobacilli and a vaginal pH greater than 4.5.
LGM Pharma is a provider of Clindamycin Hydrochloride & Clindamycin Phosphate for research and development purposes. Clients can be assured of continued support from LGM Pharma throughout the R&D process.
Products currently covered by valid US Patens are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.